Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, spoke on antibiotic use and other risk factors for the development of Clostridioides difficile infection.
Risk factors for the development of Clostridioides difficile infection (CDI) include antibiotic use, elderly age, proton pump inhibitor (PPI) use, and immunosuppression, with burden of disease ranging from mild to fulminant, said Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital.
Transcript
Can you speak on risk factors for the development of CDI in the hospital setting and the associated burden of disease for those infected?
Unfortunately, C difficile remains at epidemic levels. It is the most common cause of health care–associated infection in the United States, and there are several risk factors for a primary infection. The main risk factor still remains antibiotic use, and I often get asked, well, what's a good antibiotic or a safe antibiotic? And unfortunately, there isn't one.
All antibiotics portend some risk for CDI, although certainly some, such as clindamycin, have a higher risk than others. So, we really want to do antibiotic stewardship and avoid unnecessary antibiotic use. Other risk factors include elderly age, PPI [proton pump inhibitor] use, and immunosuppression.
So, with regards to the burden of disease, there is a real range. Disease can be asymptomatic to mild to fulminant. And so generally speaking, when we think about disease, we have categories based on our guidance. So, those with nonsevere disease are typically those with diarrheal illness, who are otherwise OK and out of the hospital. Those with severe disease are typically hospitalized patients who are having more profound diarrhea and may be exhibiting signs of dehydration, such as kidney failure. And then patients with fulminant disease can be critically ill and in the ICU [intensive care unit], and already have evidence of end-organ damage, such as very low blood pressure, and needing medication support for that blood pressure.
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Understanding TB Symptoms, Spread, Treatment Amid Kansas City Outbreak
February 13th 2025In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.
Read More
Advancing Integrated Care for Comorbid Schizophrenia and Substance Use Disorder
February 11th 2025Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, outlines the progression of treatment approaches for comorbid schizophrenia and substance use disorder.
Read More